

Toll-like receptor 4 antagonists - Pipeline Insight, 2022

<https://marketpublishers.com/r/T3712D16065EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: T3712D16065EN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Toll-Like Receptor 4 (TLR-4) Agonist - Pipeline Insight, 2022" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Toll-Like Receptor 4 (TLR-4) Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Toll-Like Receptor 4 (TLR-4) Agonist Understanding

Toll-Like Receptor 4 (TLR-4) Agonist: Overview

The activation of toll-like receptor 4 (TLR4) has been proposed to have a major influence on the inflammatory signalling pathways of the intestinal tract. Inhibition of TLR4 has been postulated as an effective way to treat intestinal inflammation. However, there are a limited number of studies looking into the potential of TLR4 antagonism as a therapeutic approach for intestinal inflammation.

Toll-like receptors (TLRs) are type 1 transmembrane proteins belonging to the wider family of pattern recognition receptors, and are responsible for the recognition of a variety of molecular signals, including endogenous damage and pathogen-associated signals, damage-associated molecular patterns (DAMPs) and pathogen-associated

molecular patterns (PAMPs), respectively. TLR4 is an intra- and extracellular receptor expressed on endosomes and cytoplasmic membranes, which recognizes PAMPs (flagellin and LPS) and DAMPS (calprotectin, S100A8/9 HMGB1 and HSP70) through its co-receptors MD2 and CD14.

Targeting TLR4 could represent a potential approach to regulate immune responses and treat inflammation. However, any potential therapeutic agent must be able to block the harmful effects of TLR4 activation without negatively affecting the host's defence functions. Anti-TLR4 therapies present a promising alternative for future innovative treatments for both inflammatory bowel disease and intestinal mucositis.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Toll-Like Receptor 4 (TLR-4) Agonist R&D. The therapies under development are focused on novel approaches for Toll-Like Receptor 4 (TLR-4) Agonist.

Toll-Like Receptor 4 (TLR-4) Agonist Emerging Drugs Chapters

This segment of the Toll-Like Receptor 4 (TLR-4) Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Toll-Like Receptor 4 (TLR-4) Agonist Emerging Drugs

E-5564: Eisai

E-5564 (Eritoran) is a TLR (Toll-Like Receptor) 4 antagonist created with natural product organic synthesis technology. It is a structural analogue of Lipid A which is an activator of endotoxins of bacteria. It is expected to suppress inflammation and increasing in severity caused by COVID-19 by inhibiting the activation of TLR4, which is found in the most upstream position of various cytokine gene expression signaling that causes the cytokine-storm. Development is in collaboration with GCAR (Global Coalition for Adaptive Research).

It is currently in Phase III stage of development and is being developed by Eisai.

TAK-242: Akaza Bioscience

TAK-242 acts as inhibitor of Toll-like receptor 4. Akaza Bioscience is preparing to run a Phase II study of TAK-242, a novel immunological therapy. This pan-European study aims to investigate the safety and efficacy of TAK-242, as measured by changes in key biomarkers and 28-day survival rates. The trial will be a randomised, double-blind, placebo-controlled study in patients with Grade 1 or 2 ACLF.

It is currently in Phase II stage of development and is being developed by Akaza Bioscience.

Further product details are provided in the report.....

Toll-Like Receptor 4 (TLR-4) Agonist: Therapeutic Assessment

This segment of the report provides insights about the different Toll-Like Receptor 4 (TLR-4) Agonist drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Toll-Like Receptor 4 (TLR-4) Agonist

There are approx. 10+ key companies which are developing the Toll-Like Receptor 4 (TLR-4) Agonist. The companies which have their Toll-Like Receptor 4 (TLR-4) Agonist drug candidates in the most advanced stage, i.e. Phase III include, Eisai.

Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Toll-Like Receptor 4 (TLR-4) Agonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Toll-Like Receptor 4 (TLR-4) Agonist: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Toll-Like Receptor 4 (TLR-4) Agonist therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Toll-Like Receptor 4 (TLR-4) Agonist drugs.

Toll-Like Receptor 4 (TLR-4) Agonist Report Insights

Toll-Like Receptor 4 (TLR-4) Agonist Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Toll-Like Receptor 4 (TLR-4) Agonist Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Toll-Like Receptor 4 (TLR-4) Agonist drugs?

How many Toll-Like Receptor 4 (TLR-4) Agonist drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Toll-Like Receptor 4 (TLR-4) Agonist?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Toll-Like Receptor 4 (TLR-4) Agonist therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Toll-Like Receptor 4 (TLR-4) Agonist and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Eisai

Akaza Bioscience

OPNT-003

GeNeuro

MN-166 (ibudilast)

Orexo

Key Products

E5564

TAK-242

OPNT-003

Temelimab

MediciNova

OX125

Contents

Introduction

Executive Summary

Toll-Like Receptor 4 (TLR-4) Agonist: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Toll-Like Receptor 4 (TLR-4) Agonist– DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Toll-Like Receptor 4 (TLR-4) Agonist companies' collaborations, Licensing, Acquisition -Deal Value Trends

Toll-Like Receptor 4 (TLR-4) Agonist Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

E5564: Eisai

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

TAK-242: Akaza Bioscience

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

OX125: Orexo

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Preclinical and Discovery Stage Products

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Toll-Like Receptor 4 (TLR-4) Agonist Key Companies

Toll-Like Receptor 4 (TLR-4) Agonist Key Products

Toll-Like Receptor 4 (TLR-4) Agonist- Unmet Needs

Toll-Like Receptor 4 (TLR-4) Agonist- Market Drivers and Barriers

Toll-Like Receptor 4 (TLR-4) Agonist- Future Perspectives and Conclusion

Toll-Like Receptor 4 (TLR-4) Agonist Analyst Views

Toll-Like Receptor 4 (TLR-4) Agonist Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Toll-like receptor 4 antagonists

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Toll-like receptor 4 antagonists

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Toll-like receptor 4 antagonists - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/T3712D16065EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T3712D16065EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970